176 compound fragment screen to preclinical candidates

**Novel allostERIC protease-helicase inhibitors for HCV**

**Allosteric site of protease-helicase (NS3) protein**

**Novel mechanism of action**

**First disclosure of candidate structures**

**Differentiated chemical space to active site protease inhibitors**

**Compound 1**
- IC$_{50}$ ~ 500 µM
- LE = 0.30
- MW = 199

**Compound 3**
- IC$_{50}$ = 1.3 µM
- LE = 0.42
- MW = 280

**Compound 4**
- IC$_{50}$ = 0.10 µM
- LE = 0.38
- MW = 365

**Fragment hit**

**Optimised primary benzylamine**

**Lead**

MW <420

\[ \text{cLogP} \leq 2 \]